This award recognizes researchers whose work demonstrates exceptional originality, independence of thought, and significant impact in the field of diabetes research. Timo Müller’s pioneering discoveries have reshaped the scientific understanding of obesity and diabetes, providing foundational insights into central nervous system GIP receptor biology and paving the way for the development of next-generation incretin-based polyagonists. His work has substantially advanced therapeutic strategies and opened new avenues for the treatment of metabolic diseases.
With more than 200 publications in leading scientific journals, Müller is widely recognized as a global leader in metabolic research, driving transformative advances in diabetes science and metabolic medicine.
“The ADA is pleased to recognize these individuals and the vital role they play in advancing our mission to prevent and cure diabetes and improve the lives of all people affected by diabetes. Their incredible contributions are moving us closer to a world free of diabetes and all its burdens,” said Charles “Chuck” Henderson, Chief Executive Officer of the ADA.
The award recipients will be honored during an awards ceremony at the ADA’s 2026 Scientific Sessions, taking place in June. The Scientific Sessions represent the world’s largest scientific meeting dedicated to diabetes research, prevention, and care.
About the American Diabetes Association
The American Diabetes Association (ADA) is a leading nonprofit health organization in the United States, focused on the prevention and treatment of diabetes as well as supporting people living with the condition.
Contact
Prof. Dr. Timo Müller
Institute Director, Head of Research Unit Molecular Pharmacology
